BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional) | RFA NS 20 006

Opportunity Information: Apply for RFA NS 20 006

The NIH BRAIN Initiative funding opportunity "Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)" (RFA-NS-20-006) supports research aimed at better understanding how existing neural stimulation and neural recording technologies actually interact with the nervous system. The motivation is practical and foundational: before the field can reliably control or monitor specific cell types and neural circuits in the central nervous system, researchers need a clearer, evidence-based picture of what current tools are doing at the membrane, cellular, and circuit levels, what unintended or adaptive biological effects they may trigger over time, and what information is truly contained in the signals these tools record. The announcement is framed around improving the scientific understanding behind widely used approaches to stimulating and recording from both neuronal and non-neuronal cells, rather than inventing brand-new devices or pushing toward therapeutic translation.

The RFA invites applications in two connected but distinct research tracks. The first track focuses on stimulation: projects should systematically characterize, model, and validate the biological responses produced by different stimulation technologies. This includes work that looks across multiple scales of biology, such as membrane biophysics, cellular physiology, circuit-level effects, and longer-term adaptive responses that occur with repeated or chronic stimulation. Importantly, the scope explicitly includes not only neurons but also non-neuronal cells, recognizing that glia, vasculature-associated cells, and other components of neural tissue can shape or be altered by stimulation in ways that influence interpretation and outcomes. The expectation is that investigators will produce rigorous experimental and/or computational frameworks that clarify mechanisms, thresholds, variability, and context dependence of stimulation effects, so that future neuroscience studies can use these technologies more predictably and interpret results more accurately.

The second track centers on recording: projects should determine the biological meaning and bioinformatic content of signals captured from neural cells and circuits. In other words, the goal is not simply to collect recordings, but to figure out what recorded signals represent, how they relate to underlying cellular and circuit activity, how non-neuronal contributions or artifacts may influence signals, and how the information embedded in recordings can be more faithfully decoded and interpreted. This can include analyses that bridge biological ground truth and signal features, and efforts that clarify how recording modalities map onto specific physiological events. The emphasis on both "biological" and "bioinformatic" content signals that the FOA welcomes work combining experimental neuroscience with quantitative analysis, modeling, and data interpretation methods, as long as the core aim is understanding what the signals mean rather than developing a new recording platform.

Several boundaries are clearly stated. Developing entirely new technologies is outside the scope, as are therapeutic development efforts and the creation of new disease models. The FOA is meant to strengthen the mechanistic and interpretive foundation for tools already in use, not to fund technology invention pipelines or translational programs. At the same time, the announcement allows projects that enable the simultaneous use of multiple stimulation or recording technologies, which can be important for cross-validation, ground-truthing, and understanding interactions among modalities (for example, pairing stimulation with concurrent recording, or comparing signals across different recording approaches).

Mechanistically, this is an NIH R01 grant mechanism with clinical trials listed as optional, meaning applicants may propose clinical trial elements if they are appropriate and justified, but a clinical trial is not required. The sponsoring agency is the National Institutes of Health, and the opportunity sits within NIH's broader BRAIN Initiative goals related to measuring and manipulating neural circuit activity with greater specificity and reliability. The funding opportunity is categorized as discretionary and uses the standard NIH grant funding instrument.

Eligibility is broad and includes many common applicant organizations, such as public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district), as well as independent school districts and public housing authorities/Indian housing authorities. The eligible applicant pool also explicitly includes a wide range of mission-specific or community-rooted institutions and entities, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). In addition, eligible applicants include certain tribal governments and organizations, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, eligible federal agencies, and even non-U.S. (foreign) organizations, reflecting NIH's interest in supporting strong science wherever it is based, provided it meets NIH requirements.

Key identifiers provided in the source data include the Funding Opportunity Number RFA-NS-20-006 and multiple CFDA program numbers (93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867). The opportunity was created on 2020-01-02 and listed an original closing date of 2022-10-03, indicating it is a dated solicitation rather than an always-open program announcement.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867.
• This funding opportunity was created on 2020-01-02.
• Applicants must submit their applications by 2022-10-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 20 006

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: